MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Sitges, España
Joined March 2017
- Tweets4.4K
- Following611
- Followers3.6K
- Likes10.3K
Noemi Reguart retweeted
A true tour de force by the amazing @DrJNaidoo at #ESMO26 Presidential Symposium! 👏🔥
A masterclass in how to discuss a negative trial: sharp, insightful, and extracting every important message for our oncology community.
And doing it all while waiting for the new member of the family! ❤️ A powerful #WomenForOncology role model! Absolutely WOW! 🌟💪💪
#ESMO2026 #W4O @myESMO
Noemi Reguart retweeted
🔥 Outstanding piece of work published today in Nature Medicine!
Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏
The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy?
This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients.
Congratulations to everyone involved! 👏
🔗 nature.com/articles/s41591-0…
Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors
#ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch
Noemi Reguart retweeted
#ESMO26 Today the thoracic oncology community celebrates:
🏆 The major advances in the fight against lung cancer reported at @myESMO
🎉The birthday of @JordiRemon 🥳 (great discussant!)
🐣 The new member of the lung cancer family on the way!!! ….and the best ever pregnant discussant of all times @DrJNaidoo
So happy to be part of this superfamily
May God bless you all and our patients
#ESMOAmbassadors
Noemi Reguart retweeted
#ESMO26 Highly recommend watching Dr. Tina Cascone in this lung education session for a mechanistic view of novel immunotherapy agents. Clear explanation of how function follows structure, the science behind bispecifics and trispecifics - combinatorial vs obligate. Watch online - tremendous resource for anyone involved in the space. #ESMOAmbassadors
Noemi Reguart retweeted
Small-cell lung cancer is one of the most aggressive and lethal cancers worldwide. Although treatments have improved overall survival, most patients ultimately have disease progression. Research findings from the phase 3 TAISHAN-302 trial are summarized in a new Quick Take video. nej.md/4hZz1CY
ALT The image is a visual representation of the TAISHAN-302 trial, which assessed tambotatug pelitecan (Tam-Peli), a B7-H3–targeting antibody–drug conjugate, to treat patients with small-cell lung cancer.
Noemi Reguart retweeted
⭕ El GECP presenta en formato póster en #ESMO26 el trabajo:
🗣️ “Pathological complete response explains part, but not all, of the survival benefit in NADIM II: a causal mediation analysis”
👉 El análisis, encabezado por @MARIANOPROVENCI y @bmassuti2 , profundiza en el papel de la respuesta patológica completa y su contribución al beneficio en supervivencia observado en #NADIMII
Noemi Reguart retweeted
⭕El GECP presenta en formato póster en #ESMO26 el trabajo:
👉 “Impact of Residential Radon Exposure on the Molecular Profile of Lung Cancer in Spain: Results from the RTT-ATLAS-Radon Study”
🗣️ La investigación, encabezada por @VirginiaCalvo6 y con la participación de @albertoruano8 , analiza la relación entre la exposición residencial al radón y las características moleculares del cáncer de pulmón en España
RT @StephenVLiu: The lung cancer community at #ESMO26 Presidential Symposium III here for Dr. Jarushka Naidoo (+1) @DrJNaidoo - discussant…
Noemi Reguart retweeted
#ESMO26 Dr. Chongrui Xu presents phase III HERON-Lung01 trial: ruzaltatug rezetecan (HER3 ADC) vs platinum chemo in EGFR NSCLC post TKI. ADC superior: PFS 8.3 vs 5.4m, HR 0.47 with OS trend (HR 0.70, ns) despite crossover. RR 60% vs 34% Low rates of discontinuation, ILD rate 2.4% and most toxicity hematologic. #ESMOAmbassadors
Noemi Reguart retweeted
Iza-Bren seems to provide efficacy in pretreated EGFR-mutated NSCLC compared to pt-based chemotherapy.
Better ORR and PFS, OS still immature, safety profile not such favorable compared to chemotherapy. Interesting to see global data, optimized AEs management. Good to have more potential options available. #ESMO26 #LCSM
Noemi Reguart retweeted
#ESMO26 Dr. Ziming Li with phase III study of dalmelitinib + aumolertinib vs platinum chemo in EGFR+ NSCLC with MET amp post EGFR TKI. PFS favors TKIs: 6.2m vs 4.4m, HR 0.60; OS immature and high crossover (HR 0.84). RR 60% vs 39%. Higher d/c rate with TKIs. #ESMOAmbassadors
Noemi Reguart retweeted
Simultaneous publication @NEJM of #ESMO26 presentation from Dr. Shun Lu. Osimertinib + savolitinib superior to chemo in EGFR+ NSCLC post osimertinib with MET overexpression and/or amp: 338 randomized / 1746 screened: PFS 7.6 vs 5.4m, HR 0.55, OS HR 0.68
nejm.org/doi/full/10.1056/NE…
Noemi Reguart retweeted
#ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs 34.9m, HR 0.48. RR 81% vs 68%. Toxicities below. Very impressive. #ESMOAmbassadors
Noemi Reguart retweeted
#ESMO26 Dr. Li Zhang presents PANKU-Lung01: phase III izalontamab brengitecan (iza-bren, HER3:EGFR ADC) vs platinum based chemo in EGFR+ NSCLC after 3G TKI. Iza bren improved PFS: 11.1 vs 5.7m, HR 0.40! OS immature but 1y rates 83% vs 73%. High reduction/interruption rates but low discontinuation rates. Most common toxicities were hematologic in nature. Very exciting data here: ADCs here to stay. #ESMOAmbassadors
Noemi Reguart retweeted
#ESMO26 : A great brainstorming summit on #SCLC organized by @LungSummit in a fully packed auditorium+overflow following yesterday’s announcement of DeLlphi-305;
➡️ The chemoIO landscape in 1L @MartinReck2
➡️ T-cell engager clinical development @peters_solange
➡️ Management οf CRS and ICANS @g_mountzios
➡️ Sequencing and combinations @NReguart
A heartfelt 🙏 for your presence, interaction and tons of questions!!!
#ESMOAmbassadors
Noemi Reguart retweeted
Savo + Osi >>> Osi
In 1L stage IV, EGFRmut: Better PFS and remarkable 44.5 OS for a poor prognosis population, with the cost of more MET-related side effects.
High attrition to find MET-IHC3+. Wondering how this data compares to this subset of patients in the MARIPOSA trial. #ESMO26 #LCSM
Noemi Reguart retweeted
✨ PRACTICE CHANGING ✨ data from #ESMO26
Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer
@FSkoulidis presents results from Krascendo 1
Divarasib significantly prolongs PFS and OS with a more tolerable safety profile
